Aakriti Gupta

Aakriti Gupta

Auto-generated profile, based on publicly available information

Aakriti Gupta

Karsh Center for Interventional Cardiology, Smidt Heart Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 March 2021 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
ANAni Nalbandian
Ani Nalbandian
KSKartik Sehgal
Kartik Sehgal
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
CMClaire McGroder
Claire McGroder
EWElaine Y. Wan
Elaine Y. Wan

10 July 2020 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
KSKartik Sehgal
Kartik Sehgal
NNNandini Nair
Nandini Nair
SMShiwani Mahajan
Shiwani Mahajan
DLDonald W. Landry
Donald W. Landry

26 February 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
AGAakriti Gupta
Aakriti Gupta
MMMahesh V. Madhavan
Mahesh V. Madhavan
TPTimothy J. Poterucha
Timothy J. Poterucha
EDErsilia M. DeFilippis
Ersilia M. DeFilippis
JHJessica A. Hennessey
Jessica A. Hennessey
SPSahil A. Parikh
Sahil A. Parikh
The coronavirus disease 2019 (COVID-19) can result in a hyperinflammatory state, leading to acute respiratory distress syndrome (ARDS), myocardial injury, and thrombotic complications, among other sequelae. Statins, which are known to have anti-inflammatory and antithrombotic properties, have been studied in the setting of other viral infections, but their benefit has not been assessed in COVID-19. This is a retrospective analysis of patients admitted with COVID-19 from February 1st through May 12th, 2020 with study period ending on June 11th, 2020. Antecedent statin use was assessed using medication information available in the electronic medical record. We constructed a multivariable logistic regression model to predict the propensity of receiving statins, adjusting for baseline sociodemographic and clinical characteristics, and outpatient medications. The primary endpoint includes in-hospital mortality within 30 days. A total of 2626 patients were admitted during the study period, of whom 951 (36.2%) were antecedent statin users. Among 1296 patients (648 statin users, 648 non-statin users) identified with 1:1 propensity-score matching, statin use is significantly associated with lower odds of the primary endpoint in the propensity-matched cohort (OR 0.47, 95% CI 0.36–0.62, p < 0.001). We conclude that antecedent statin use in patients hospitalized with COVID-19 is associated with lower inpatient mortality.

5 January 2021 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
TPTimothy J. Poterucha
Timothy J. Poterucha
PEPierre Elias
Pierre Elias
SJSneha S. Jain
Sneha S. Jain
GSGabriel Sayer
Gabriel Sayer
BRBjorn Redfors
Bjorn Redfors
EWElaine Y. Wan
Elaine Y. Wan
Background: Cardiovascular involvement in coronavirus disease 2019 (COVID‐19) is common and leads to worsened mortality. Diagnostic cardiovascular studies may be helpful for resource appropriation and identifying patients at increased risk for death. Methods and Results: We analyzed 887 patients (aged 64±17 years) admitted with COVID‐19 from March 1 to April 3, 2020 in New York City with 12 lead electrocardiography within 2 days of diagnosis. Demographics, comorbidities, and laboratory testing, including high sensitivity cardiac troponin T (hs‐cTnT), were abstracted. At 30 days follow‐up, 556 patients (63%) were living without requiring mechanical ventilation, 123 (14%) were living and required mechanical ventilation, and 203 (23%) had expired. Electrocardiography findings included atrial fibrillation or atrial flutter (AF/AFL) in 46 (5%) and ST‐T wave changes in 306 (38%). 27 (59%) patients with AF/AFL expired as compared to 181 (21%) of 841 with other non‐life‐threatening rhythms ( P <0.001). Multivariable analysis incorporating age, comorbidities, AF/AFL, QRS abnormalities, and ST‐T wave changes, and initial hs‐cTnT ≥20 ng/L showed that increased age (HR 1.04/year), elevated hs‐cTnT (HR 4.57), AF/AFL (HR 2.07), and a history of coronary artery disease (HR 1.56) and active cancer (HR 1.87) were associated with increased mortality. Conclusions: Myocardial injury with hs‐cTnT ≥20 ng/L, in addition to cardiac conduction perturbations, especially AF/AFL, upon hospital admission for COVID‐19 infection is associated with markedly increased risk for mortality than either diagnostic abnormality alone.

21 May 2025 in JACC
Verified
Journal Article
Closed access
RMRaj R. Makkar
Raj R. Makkar
TCTarun Chakravarty
Tarun Chakravarty
AGAakriti Gupta
Aakriti Gupta
OSOsama Soliman
Osama Soliman
EGEric Gnall
Eric Gnall
MRMichael J. Reardon
Michael J. Reardon

14 August 2020 in The American Journal of Medicine
Verified
Journal Article
Closed access
AGAakriti Gupta
Aakriti Gupta
STSui Tsang
Sui Tsang
AHAlexandra Hajduk
Alexandra Hajduk
HKHarlan M. Krumholz
Harlan M. Krumholz
MNMichael G. Nanna
Michael G. Nanna
SCSarwat I. Chaudhry
Sarwat I. Chaudhry